Lyra Therapeutics Delisted from Nasdaq, Declared 'Public Shell' Amid R&D Suspension and Liquidation Efforts
LYRA sits 58% above its 52-week low of $0.31 on light trading volume (0.1× avg).
Summary
Lyra Therapeutics has been delisted from Nasdaq, declared a 'public shell,' and suspended all R&D, facing substantial doubt about its ability to continue as a going concern.
Key Events · Corporate Governance and Compliance · LYRA
-
Nasdaq Delisting and 'Public Shell' Status
The company was delisted from The Nasdaq Capital Market on March 17, 2026, after ceasing appeal efforts. Nasdaq determined the company is a 'public shell' with no operating business, raising concerns about market abuses.
-
Suspension of All Product Development
In January 2026, the company announced the suspension of further development for its lead product candidate, LYR-210, despite positive Phase 3 ENLIGHTEN 2 results in June 2025. All R&D activities have ceased.
-
Significant Workforce Reductions and Restructuring
The company implemented a 75% workforce reduction (87 employees) in May 2024 and a further reduction of 25 employees in January 2026, impacting substantially all remaining staff. The CEO and CFO are now retained as consultants.
-
Going Concern Doubt and Limited Liquidity
Management has concluded there is 'substantial doubt' about the company's ability to continue as a going concern, with cash and cash equivalents of $15.9 million at December 31, 2025, expected to fund operations only into the third quarter of 2026.
Analysis · LYRA · Industrial Applications And Services
This 10-K filing confirms Lyra Therapeutics' severe financial distress and operational collapse. The company has been delisted from Nasdaq and deemed a 'public shell' due to the suspension of all product development, significant workforce reductions, and negative stockholders' equity. With cash and cash equivalents of only $15.9 million at year-end 2025 and a projected cash runway into Q3 2026, the company explicitly states 'substantial doubt about its ability to continue as a going concern.' The termination of its shelf registration statements further indicates an inability to raise capital through public markets. Investors face a high risk of total loss as the company explores strategic alternatives, including potential bankruptcy or liquidation.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 39.7% of the 353 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LYRA was trading at $0.49 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $871.6K. The 52-week trading range was $0.31 to $418.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.